
    
      This is a multicenter, prospective, parallel arm study to assess patients who participated in
      the VAST trial and receiving either viable allograft, saline, or allograft after cross-over.
      These patients will be evaluated at baseline, injection, 6 months, and 12 months. Subjects
      will then have an option for a 24 months and 36 months extension after their index
      procedures. Patients who received saline or active allograft in the VAST study will be
      allowed to receive viable allograft and followed for an additional 12 and 24 months after
      that election. These subjects will need to meet initial inclusion/exclusion criteria again
      before another injection.
    
  